AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03552757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo II (Semaglutide)
Description: S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
Study NCT03552757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo II (Semaglutide)
Description: S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
Study NCT03256110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Communication about Serious Illness-AI/AN
Description: A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.
Study NCT03305237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big Breakfast
Description: Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at breakfast (percent daily calories split between breakfast, lunch and dinner as 45-35-20%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
Study NCT03305237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big Dinner
Description: Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at dinner (percent daily calories split between breakfast, lunch and dinner as 20-35-45%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
Study NCT00813046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
Study NCT04696419 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Different intensities of contact to dogs
Description: Each subject is exposed to four test situations of 10 minutes. Three situations with increasing intensity of dog contact, and one control test situation with no contact to a dog. The order of the test situations is random and with 30 minute washout in-between
Study NCT04099888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimaporfin and Gemcitabine
Description: PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
Study NCT04099888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin chemotherapy
Description: Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
Study NCT04099888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/Cisplatin chemotherapy
Description: Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
Study NCT03400384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct-to-consumer educational brochure
Description: The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
Study NCT01074710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [2-13C] uracil
Description: po, in the form of semi-solid meal, granules, once a period
Study NCT01074710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [2-13C] uracil, placebo
Description: po, in the form of semi-solid meal, granules, once a period
Study NCT01684969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 0.5 mg iv x one dose
Study NCT01684969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mg iv , one dose
Study NCT01652001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malic Acid
Description: Oral spray for application into the oral cavity
Study NCT01652001 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral spray for application into the oral cavity
Study NCT01652079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: q 14 days
Study NCT04518176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral uterine artery ligation
Description: The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally
Study NCT04518176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 20 units by slow intravenous drip injection
Study NCT04518176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 units by slow intravenous drip injection
Study NCT01626664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: 1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
Study NCT01626664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pralatrexate
Description: 30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
Study NCT01626664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine plus oxaliplatin
Description: gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
Study NCT01626664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHAP
Description: dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
Study NCT04566809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES+CBA
Description: The experimental treatment was formerly composed by 20 sessions of FES for the hand in combination with a structured cognitive therapy
Study NCT04566809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES
Description: The control treatment was formerly composed by 20 sessions of FES for the hand
Study NCT04705142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSo4
Description: Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
Study NCT03784456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25% protein
Description: Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
Study NCT03784456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 15% protein
Description: Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
Study NCT03836209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Induction: 120 mg orally daily x 14 days starting on day 8~Consolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)
Study NCT03836209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midostaurin
Description: Induction: 50 mg orally twice daily x 14 days beginning on day 8~Consolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)
Study NCT03836209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3~Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3
Study NCT03836209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3~Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3
Study NCT03836209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles
Study NCT03836209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles
Study NCT03520673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urodynamics
Description: All the men in the study will receive the urodynamics procedure as a reference test.
Study NCT01282359 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical practice group
Description: Clinical practice group will not receive any specific education
Study NCT01282359 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gold Standard educational group
Description: Gold Standard educational group will receive a formal program of structured and individualized education
Study NCT01282359 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Intervention group will take the limited educational asthma program which have three parts: basic information, establishment and revision of a small Action Plan (MiniPlan) and training and review of the inhalation skill of the prescribed device. Educators involved will attend a short workshop (6 h), where they will be trained in the program.
Study NCT02863575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/Caffeine
Description: Ibuprofen/Caffeine fixed-dose combination
Study NCT02863575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen capsule
Study NCT02863575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study NCT06316609 — intervention group
Intervention type: OTHER
Intervention: Gestational Exposure to Emerging Contaminants (ECs)
Description: Levels of Emerging Contaminants (ECs), such as Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics, are assessed in maternal blood and umbilical cord blood during gestation.
Study NCT02483975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Study NCT02483975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Study NCT02483975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast will be provided as 4 mg and 5 mg chewable tablets.
Study NCT02483975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: Montelukast will be provided as 4 mg and 5 mg chewable tablets.
Study NCT02483975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Albuterol/Salbutamol will be provided as inhalation aerosol.
Study NCT02483975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Albuterol/Salbutamol will be provided as inhalation aerosol.
Study NCT04960488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy and coronary artery bypass grafting
Description: carotid endarterectomy and coronary artery bypass grafting
Study NCT04960488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carotid endarterectomy and coronary artery bypass grafting
Description: carotid endarterectomy and coronary artery bypass grafting
Study NCT00048048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration
Study NCT02602379 — intervention group
Intervention type: OTHER
Intervention: Tetanic stimulation
Description: Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant potassium 150 mg
Description: Telcagepant 150 mg liquid-filled soft gel capsules
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant potassium 300 mg
Description: Telcagepant 300 mg liquid-filled soft gel capsules
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolmitriptan 5 mg
Description: Zolmitriptan 5 mg tablets
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to telcagepant 150 mg
Description: Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to telcagepant 150 mg
Description: Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to telcagepant 150 mg
Description: Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to tecagepant 300 mg
Description: Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tecagepant 300 mg
Description: Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to tecagepant 300 mg
Description: Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to zolmitriptan 5 mg
Description: Placebo to match zolmitriptan 5 mg tablets
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zolmitriptan 5 mg
Description: Placebo to match zolmitriptan 5 mg tablets
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
Study NCT00442936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
Study NCT03316729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-9231
Description: DS-9231 in saline solution for intravenous infusion
Study NCT03316729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is matching saline solution for intravenous infusion
Study NCT04556214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplant
Description: Liver Transplant
Study NCT01900509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
Study NCT01900509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Route of administration: IV days 1-5.
Study NCT01900509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Route of administration: IV days 1-5.
Study NCT01900509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
Study NCT01900509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Route of administration: three times daily orally (by mouth), days 1-5.
Study NCT03629925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, Q3W, day1, I.V.; consecutive cycles
Study NCT03629925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m\^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
Study NCT03629925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m\^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
Study NCT03629925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m\^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
Study NCT03629925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
Study NCT03629925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NA, Q3W, day1, I.V.; consecutive cycles
Study NCT03629925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
Study NCT03629925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
Study NCT03695926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-1054
Description: Healthy volunteers recruited for the study will undergo a \[18F\]MNI-1054 PET scan.
Study NCT01893957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high voltage electrical stimulation - axillary lymphadenectomy
Description: Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
Study NCT01893957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High voltage electrical stimulation - ( healthy women )
Description: Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
Study NCT01893957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurodyn High Volt Model (IBRAMED)
Study NCT02590861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant
Description: All participants will receive the same intervention, this is a single group study.
Study NCT00369590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study NCT00369590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative studies
Study NCT00369590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative studies